Problematic Psychedelics? Psychedelics and mental health treatment go together like orange juice and toothpaste. That’s what I would have said five years ago. Prior to the publication of multiple…
FH.NEO
Today, Jody sits down once again with Ben Lightburn, CEO, director and co-founder of Filament Health (FH.NEO). Ben catches us up on the progress the medical psychedelics company has…
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
Filament Health (FH.NE) has released two new press releases since the last time I covered the company back in mid January 2022. Filament Health Corp. operates as a natural psychedelic…
Filament Health (FH.NE) announced today that it has received approval from Health Canada for a Phase 2 clinical trial using PEX010, the Company’s botanical psilocybin drug candidate. Cybin Therapeutics…
Environmental, Social and Governance (ESG) focused investment is a relatively new accepted method for socially conscious investors to allocate their investment capital in public/private companies that align with their…
A Change In Stance Filament Health Corp (FH.NE) announced today that Psilo Scientific Ltd., the Company’s wholly-owned subsidiary, has joined Health Canada’s list of licensed psilocybin producers. No, we…
Filament Health Corp. operates as a natural psychedelic drug discovery and extraction technology company. It propagates psychedelic plants; conducts genetic research; performs extraction procedures; runs in-house trials; and distributes IP…
I’ll admit that I’m beginning to have my suspicions about the psychedelic sector. The question I’ve started asking when I look at a new psychedelics company is where’s the…
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…